Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

technetium Tc 99 MIRC213

A radioconjugate composed of a nanobody directed against human epidermal growth factor receptor 2 (HER2; EGFR2; ERBB2) that is site-specifically labeled with technetium Tc 99m, with potential use as a tracer for HER2-expressing tumors using single photon emission computed tomography/computed tomography (SPECT/CT). Upon administration of technetium Tc-99m-MIRC213, the anti-HER2 nanobody moiety targets and binds to HER2-expressing tumor cells. This allows the detection of HER2-expressing tumor cells upon SPECT/CT. HER2, a receptor tyrosine kinase, is overexpressed on the cell surfaces of various tumor cell types; it plays a key role in tumor cell proliferation and tumor vascularization.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:99mTc-MIRC208
technetium Tc 99m-MIRC213
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search